Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

How DMPK should integrate with and influence projects in discovery and beyond

With Dr Richard Weaver, Senior Vice President – Preclinical Development

The chemical structure that has, by definition, been defined in a pre-clinical candidate may have flaws that could have been designed out if the DMPK scientist had been engaged earlier. Some of these recurring issues are: inadequate solubility, an unreasonable human dose projection, unacceptable human bioavailability, a non-existent safety margin, no real target engagement or lack of understanding of PK/PD.

Richard will give a tour of DMPK influence from Drug Discovery and beyond and highlight some of the pitfalls, misconceptions and advice in order to maximise success.

View Webinar

Webinar Data Capture

Latest Webinars

View All

Degraders on The Rise – Targeted Protein…

Psychedelics and Psychiatry: A Roadmap to Evaluate…

A Tale of Two Libraries: How can…

Mouse Models of Cancer: understand their limitations…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.